SCHEMBL13265779

SCHEMBL13265779

Cc1ncccc1NC(=O)c1ccccc1Sc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.52
▸ LMNA P02545 5/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ CRHBP P24387 1/20 0.47
▸ CRHR2 Q13324 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ KDR P35968 1/20 0.46
▸ SNCA P37840 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13265682 0.85 KDR (0.66) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL13265685 0.85 MEN1 (0.63) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL13265777 0.83 MAPT (0.54) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL14537874 0.82 LMNA (0.64) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL13265843 0.81 RORC (0.59) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL29397255 0.81 ALDH1A1 (0.65) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL2954791 0.81 ALDH1A1 (0.65) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL13265774 0.79 KMT2A (0.63) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL13265845 0.79 SMN1; SMN2 (0.52) MAPTLMNAKMT2AMEN1SMN1; SMN2
SCHEMBL13265690 0.78 CYP11B2 (0.63) MAPTLMNAKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754773-B2 Composition and synthesis of new reagents for inhibition of HIV replication UNIVERSITY OF MASSACHUSETTS (US) 2010-07-13 — — US disclosed
US-20070099919-A1 Composition and synthesis of new reagents for inhibition of HIV replication NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099919-A1 Composition and synthesis of new reagents for inhibition of HIV replication REV1, MAVS, ISG15 MAPT 2825/4885LMNA 2874/4885KMT2A 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback